Literature DB >> 26696411

Updates on the Production of Therapeutic Antibodies Using Human Hybridoma Technique.

Xenia A Glukhova, Olga V Prusakova, Julia A Trizna, Michael M Zaripov, Gaida V Afanas'eva, Anatoly S Glukhov, Rimma A Poltavtseva, Alexei A Ivanov, Marco Avila-Rodriguez, George E Barreto, Gjumrakch Aliev, Igor P Beletsky1.   

Abstract

Therapeutic antibodies are implicated into the very promising and fast growing area of pharmaceutics. Human hybridoma technology, allowing generation of natural human antibodies in a native form, seems to be the most direct way that require no additional modifications for production of therapeutic antibodies. However, technical difficulties in human hybridoma creation discovered in the 80s of the last century have switched the mainstream therapeutic antibody development into new directions like display and transgenic mice techniques. These approaches have provided remarkable achievements in antibody engineering within last 15 years, but also revealed other limitations. Thus, it is time to turn back to forgotten human hybridoma technology. In this review, we describe new advances in all components of human hybridoma technology and discuss challenges in generating novel therapeutic mABs based on hybridoma technologies.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26696411     DOI: 10.2174/1381612822666151223102845

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  4 in total

Review 1.  Advances in the Isolation of Specific Monoclonal Rabbit Antibodies.

Authors:  Zaibao Zhang; Huijuan Liu; Qian Guan; Lei Wang; Hongyu Yuan
Journal:  Front Immunol       Date:  2017-05-05       Impact factor: 7.561

Review 2.  Antibody Engineering for Pursuing a Healthier Future.

Authors:  Abdullah F U H Saeed; Rongzhi Wang; Sumei Ling; Shihua Wang
Journal:  Front Microbiol       Date:  2017-03-28       Impact factor: 5.640

Review 3.  Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives.

Authors:  Hilal Ahmed Parray; Shivangi Shukla; Sweety Samal; Tripti Shrivastava; Shubbir Ahmed; Chandresh Sharma; Rajesh Kumar
Journal:  Int Immunopharmacol       Date:  2020-05-27       Impact factor: 4.932

Review 4.  Opportunities and Challenges for Antibodies against Intracellular Antigens.

Authors:  Xiaofeng Yang; Shenxia Xie; Xiaomei Yang; Juan C Cueva; Xiaoqiong Hou; Zhuoran Tang; Hua Yao; Fengzhen Mo; Shihua Yin; Aiqun Liu; Xiaoling Lu
Journal:  Theranostics       Date:  2019-10-15       Impact factor: 11.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.